S-1: Windtree Therapeutics Files for Resale of Up to 40 Million Shares Under Equity Line of Credit

Windtree Therapeutics is registering for the resale of up to 40 million shares of its common stock, issuable under an equity line of credit agreement, by a selling stockholder.

Summary

• Windtree Therapeutics has filed a registration statement for the resale of up to 40,000,000 shares of its common stock.
• These shares are issuable to Seven Knots, LLC under a common stock purchase agreement related to an equity line of credit.
• The company will not receive any proceeds from the sale of these shares by the selling stockholder, but may receive up to $23.8 million in gross proceeds from the sale of ELOC shares to the selling stockholder.
• The registration is required by the terms of the equity line agreement and a related registration rights agreement.
• The company is paying the costs of registering the shares, while the selling stockholder is responsible for selling commissions and transfer taxes.
• Windtree's common stock is traded on the Nasdaq Capital Market under the symbol WINT, with the last reported sale price on February 13, 2025, at $0.154 per share.

Sentiment

Score: 3

Explanation: The document presents a mixed picture. While it outlines a potential funding source, it also highlights significant financial challenges and risks, including a going concern warning and potential stock dilution. The overall sentiment is cautiously negative.

Positives

• The registration allows Windtree to potentially access up to $23.8 million in gross proceeds through the equity line of credit with Seven Knots, LLC.

Negatives

• The sale of a substantial number of shares by the selling stockholder could cause the price of Windtree's common stock to decline.
• The company will not receive any proceeds from the sale of these shares by the selling stockholder.

Risks

• The sale of a substantial number of shares of common stock by the selling stockholder could cause the price of our common stock to decline.
• You may experience future dilution as a result of future equity offerings and other issuances of our securities.
• Our current cash position, losses, negative cash flows from operations and accumulated deficit raise substantial doubt about our ability to continue as a going concern absent obtaining adequate new debt or equity financings. We do not have sufficient resources available to fund our business beyond mid-March 2025.
• We have incurred significant operating losses since inception, we expect to incur operating losses in the future, and we may not be able to achieve or sustain profitability.
• We have incurred indebtedness, which could adversely affect our operating flexibility and financial condition.
• If we fail to maintain proper and effective internal control over financial reporting, our ability to produce accurate and timely financial statements could be impaired, investors may lose confidence in our financial reporting and the trading price of our common stock may decline.
• We are substantially dependent on the success of our lead product candidate, istaroxime. To the extent that our clinical development of istaroxime is not successful, our business, financial condition, and results of operations may be materially adversely affected and the price of our common stock may decline.
• Although we have multiple product candidates or potential indications of those candidates in our clinical pipeline, we may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on other product candidates or indications that may be more profitable or for which there is a greater likelihood of success.
• We rely on third parties, primarily outside of the U.S., to conduct many of our preclinical studies and clinical trials. Any failure by a third party to conduct the clinical trials according to good clinical practices, and other requirements and in a timely and quality manner may delay or prevent our ability to seek or obtain regulatory approval for or commercialize our product candidates.
• We plan to rely on third parties, some of which are located outside the U.S., to manufacture our drug product candidates, which exposes us to risks that may affect our ability to maintain supplies of our clinical materials, and subject us to uncertainty associated with the international political climate, and could potentially delay or cease our research and development activities, as well as eventual regulatory approval and commercialization of our drug product candidates.
• Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations or any guidance we may provide.
• We may seek to enter into licensing transactions, collaboration arrangements, and other similar transactions and strategic opportunities, and may not be successful in doing so, and even if we are, we may not realize the benefits of such relationships.
• We could be adversely affected by any interruption, including from breaches in cybersecurity, in our ability to conduct business at our current location.
• Our activities are subject to various and complex laws and regulations, and we are susceptible to a changing regulatory environment. Violations or allegations of violations of these laws may result in large civil and criminal penalties, debarment from participating in government programs, diversion of management time, attention and resources and may otherwise have a material adverse effect on our business, financial condition and results of operations.
• We face risks related to our collection and use of data, including personal information, which could result in investigations, inquiries, litigation, fines, legislative and regulatory action and negative press about our privacy and data protection practices.
• Healthcare reform measures in the U.S., as well as the general tightening of drug reimbursement pathways and levels of reimbursement globally, are expected to add additional pressure to achieve financial expectations for our product candidates, if approved.
• Our international operations subject us to additional regulatory oversight in foreign jurisdictions, as well as economic, social, and political uncertainties, which could cause a material adverse effect on our business, financial position, and operating results.
• If we cannot protect our intellectual property, others could use our technology in competitive products. Even if we obtain patents to protect our product candidates, those patents may not be sufficiently broad, or they may expire and others could then compete with us.
• Litigation or other proceedings or third-party claims of intellectual property infringement could require us to spend significant time and money and could prevent us from selling our product candidates or affect our stock price.
• Our common stock is listed on The Nasdaq Capital Market. We can provide no assurance that we will be able to comply with the continued listing requirements over time and that our common stock will continue to be listed on Nasdaq. We are currently not in compliance with all Nasdaq continued listing requirements.
• We last effected a reverse stock split on April 19, 2024, and will need to effect a future reverse stock split to regain compliance with The Nasdaq Capital Market listing rules, which may adversely impact the market price of our common stock.
• The market price of our common stock may be highly volatile, and investors may not be able to resell their shares at or above the price at which they purchase them.
• The Series C Certificate of Designation and certain warrants issued in July 2024 (the Warrants) each contain anti-dilution provisions that may result in the reduction of the conversion price of the Series C Preferred Stock and exercise price of the Warrants. These features may increase the number of shares of our common stock being issuable upon conversion of the Series C Preferred Stock and the exercise of the Warrants.
• The Series C Preferred Stock have a liquidation preference senior to our common stock.

Future Outlook

The company may amend or supplement this prospectus from time to time by filing amendments or supplements as required.

Industry Context

The document relates to the financial operations of a biotechnology company, which is a capital-intensive industry often reliant on equity financing. The filing reflects the company's strategy to secure funding for its ongoing research and development activities.

Comparison to Industry Standards

• It's difficult to provide a direct comparison to industry standards without knowing the specific terms of the equity line of credit (ELOC) and the company's overall financial situation. However, here are some general points to consider:
• * **Equity Line of Credit (ELOC) Terms:**
• * **Discount:** A discount of 5% to the market price is fairly standard for ELOCs. Some ELOCs may have even steeper discounts (e.g., 10%).
• * **Commitment Fee:** The $25,000 expense reimbursement to Seven Knots is a relatively small commitment fee. Some ELOCs may have larger upfront fees or ongoing maintenance fees.
• * **Term:** A 24-month term is a typical timeframe for an ELOC.
• * **Limitations:** The 4.99% beneficial ownership limitation is a common provision to avoid triggering certain regulatory thresholds.
• * **Dilution:** The potential for significant dilution is a major concern for existing shareholders. A 52% increase in outstanding shares is substantial and could put downward pressure on the stock price.
• * **Going Concern:** The going concern warning is a red flag. It indicates that the company's financial situation is precarious and that it needs to raise additional capital to continue operating.
• **Comparable Companies:**
• To get a better sense of how Windtree's situation compares to its peers, you could look at other small-cap or micro-cap biotechnology companies that have used ELOCs or similar financing mechanisms. Some examples of companies that have used ELOCs in the past include:
• * **Atossa Therapeutics (ATOS):** A clinical-stage biopharmaceutical company focused on breast cancer. They have used ELOCs and other equity financings to fund their clinical trials.
• * **Citius Pharmaceuticals (CTXR):** A specialty pharmaceutical company focused on critical care and oncology. They have also used ELOCs to raise capital.
• * **Cyclacel Pharmaceuticals (CYCC):** A biopharmaceutical company focused on cancer therapies. They have used ELOCs and other equity financings to fund their research and development.
• By comparing Windtree's ELOC terms, dilution, and going concern status to those of these and other similar companies, you can get a better sense of whether its situation is typical or atypical for the industry.

Stakeholder Impact

• Shareholders may experience dilution due to the potential issuance of up to 40,000,000 shares of common stock.
• The company's ability to continue operations and develop its product candidates is dependent on securing additional funding.

Next Steps

• The selling stockholder may sell, transfer or otherwise dispose of any or all of the shares of common stock offered by this prospectus from time to time on The Nasdaq Capital Market or any other stock exchange, market or trading facility on which the shares are traded or in private transactions.

Key Dates

Keywords

common stock, resale, equity line of credit, Seven Knots LLC, registration statement, ELOC, Windtree Therapeutics, shares, securities, offering